Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NAPHAZOLINE HYDROCHLORIDE vs TYZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.
Ocular: relief of redness, itching, and irritation due to minor eye irritations or allergic conjunctivitis. Nasal: temporary relief of nasal congestion due to colds, allergies, or sinusitis.
Symptomatic relief of nasal congestion due to common cold, sinusitis, or allergic rhinitis,Off-label: relief of eustachian tube congestion
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.
Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life.
Terminal elimination half-life is approximately 3-4 hours; clinically, this supports dosing every 8-12 hours.
Not extensively studied; likely hepatic metabolism via unknown enzymes.
Primarily hepatic metabolism via oxidation and reduction pathways; no specific CYP enzymes identified.
Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine.
Renal elimination of unchanged drug and metabolites accounts for approximately 50% of the dose; fecal elimination is minimal.
Not well characterized; expected to be low (<20%) based on structural analogs.
Approximately 50% bound to plasma proteins, primarily albumin.
Not established in humans; based on animal data, approximately 0.5-1.0 L/kg, suggesting distribution into total body water.
Approximately 1.5 L/kg, indicating extensive tissue distribution beyond plasma volume.
Ophthalmic and intranasal: low systemic bioavailability due to local vasoconstriction limiting absorption; exact % not determined, estimated <1%.
Intranasal: approximately 100% (local effect); systemic bioavailability is low due to local vasoconstriction limiting absorption.
No dose adjustment required; primarily locally acting with minimal systemic absorption.
No dose adjustment required.
No dose adjustment required; use caution in severe hepatic impairment due to potential for systemic effects.
No dose adjustment required.
Children ≥6 years: 1-2 drops of 0.1% ophthalmic solution every 6-8 hours; nasal spray 0.05% for children ≥6 years, 1 spray per nostril every 8-10 hours. Contraindicated in infants and children <6 years due to risk of CNS depression.
Children 6-12 years: Instill 1-2 drops of 0.05% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day. For children under 6: Not recommended.
Elderly patients may be more sensitive to adverse effects (e.g., rebound congestion, hypertension); use lowest effective dose and shortest duration. Avoid in patients with cardiovascular disease or glaucoma.
Use with caution due to increased sensitivity and risk of adverse effects; consider lower concentration (0.05%) and limit duration of use to 3-5 days.
None
None
Prolonged use may cause rebound congestion (rhinitis medicamentosa). Use with caution in patients with cardiovascular disease (hypertension, arrhythmias), hyperthyroidism, diabetes, or prostatic hyperplasia. Avoid use in patients with narrow-angle glaucoma. Do not exceed recommended dosage or duration.
Rebound congestion (rhinitis medicamentosa) with prolonged use,Potential for systemic effects with excessive use (hypertension, palpitations),Use caution in cardiovascular disease, hypertension, hyperthyroidism, diabetes, and glaucoma
Hypersensitivity to naphazoline or any component. Narrow-angle glaucoma (ophthalmic use). Use with MAO inhibitors or within 14 days of stopping therapy (risk of hypertensive crisis).
Known hypersensitivity to tetrahydrozoline,Angle-closure glaucoma,Concurrent use with MAO inhibitors or within 14 days of discontinuation
No significant food interactions; avoid excessive caffeine or other stimulants as they may potentiate sympathomimetic effects.
None known. No specific dietary restrictions.
Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks include vasoconstriction and reduced uterine blood flow. No adequate and well-controlled studies in pregnant women. Animal studies have not been reported. First trimester: No known teratogenic effects. Second and third trimesters: Potential risk of reduced uteroplacental perfusion when used systemically; topical use at recommended doses unlikely to cause significant effects. Overall, classified as FDA Pregnancy Category C. Caution is advised.
Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no known teratogenicity but risk of maternal hypertension and reduced placental perfusion.
Excretion in human milk is unknown. Due to low systemic absorption after topical application, amounts ingested by an infant are expected to be minimal. No known adverse effects in nursing infants. M/P ratio not reported. Consider benefit of treatment versus potential risk to infant. Use caution and avoid prolonged or excessive dosing.
No data on excretion in breast milk; M/P ratio unknown. Consider risk of infant systemic effects (tachycardia, hypertension) given vasoconstrictor properties. Only use if clearly indicated and monitor infant for adverse effects.
No dose adjustments required for topical ocular or nasal use due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not significant for topical administration. Use at standard recommended doses and avoid prolonged or excessive application.
No specific pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Avoid systemic absorption (e.g., nasal spray for local effect). No dose adjustment recommended based on available evidence.
Naphazoline is a direct-acting sympathomimetic with rapid onset; use limited to 3-5 days to avoid rebound congestion and rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma due to potential mydriasis. Caution in cardiovascular disease, hypertension, and hyperthyroidism; may elevate BP and cause palpitations. Not for use in infants or children under 6 years due to risk of CNS depression.
Tyzine (tetrahydrozoline) is an imidazoline derivative with alpha-adrenergic agonist activity. It causes vasoconstriction of conjunctival blood vessels but may produce rebound hyperemia, mydriasis, and systemic effects if overused. Avoid in narrow-angle glaucoma. Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, or diabetes. Do not use longer than 72 hours to prevent rebound congestion. Contact lens wearers should remove lenses before instillation. Do not use in patients with MAOI therapy or within 14 days of discontinuation.
Do not use for more than 3-5 consecutive days to avoid worsening congestion and dependence.,Avoid contact with eyes; if eye contact occurs, flush with water for 15 minutes.,Do not share the bottle with others to prevent infection spread.,Store at room temperature, away from light and moisture.,Consult a doctor before use if you have heart disease, high blood pressure, or an enlarged prostate.
Do not use more than the recommended dose or for longer than 3 days.,Remove contact lenses before using drops and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not share the medication with others.,If you experience eye pain, vision changes, or redness lasting >72 hours, stop use and consult a doctor.,Do not use if pregnant or breastfeeding without medical advice.,Keep out of reach of children; accidental ingestion may cause serious side effects.
"Naphazoline, an alpha-1 adrenergic receptor agonist, induces vasoconstriction and elevates blood pressure. Co-administration with ergometrine, an ergot alkaloid that also causes potent vasoconstriction via serotonin and alpha-adrenergic receptor activation, results in additive or synergistic hypertensive effects. This combination significantly increases the risk of severe hypertension, hypertensive crisis, and potential end-organ damage such as stroke or myocardial ischemia."
"Naphazoline, an alpha-adrenergic agonist, can cause systemic vasoconstriction and reflex bradycardia. When combined with nadolol, a non-selective beta-blocker, the bradycardic effects may be additive, leading to an increased risk of atrioventricular (AV) block. This interaction can result in profound bradycardia, hypotension, and potential syncope, particularly in patients with pre-existing cardiac conduction abnormalities."
"Naphazoline, an alpha-adrenergic agonist with vasoconstrictive properties, can increase systemic blood pressure through peripheral vasoconstriction, which may counteract the antihypertensive effects of cyclobenzaprine, a centrally acting muscle relaxant that can lower blood pressure due to its sedative and alpha-blocking activities. This pharmacodynamic opposition may reduce the efficacy of cyclobenzaprine in managing hypertension or lead to inadequate blood pressure control. Clinically, patients may experience elevated blood pressure readings or require dose adjustments of antihypertensive therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NAPHAZOLINE HYDROCHLORIDE vs TYZINE, answered by our medical review team.
NAPHAZOLINE HYDROCHLORIDE is a Ophthalmic Decongestant that works by Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.. TYZINE is a Ophthalmic Decongestant that works by Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NAPHAZOLINE HYDROCHLORIDE and TYZINE depend on the specific clinical indication. These are both Ophthalmic Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NAPHAZOLINE HYDROCHLORIDE is: 1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.. The standard adult dose of TYZINE is: Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NAPHAZOLINE HYDROCHLORIDE and TYZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NAPHAZOLINE HYDROCHLORIDE is classified as Category C. Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks. TYZINE is classified as Category C. Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.